Статья
Роль адипокинов в регуляции функции сердечно-сосудистой системы
Жировая ткань является эндокринным органом, секретирующим сигнальные пептиды адипокины. Адипокины играют заметную роль в регуляции иммунной, эндокринной, нервной, выделительной систем организма. Дисбаланс адипокинов приводит к развитию хронического воспалительного состояния, метаболических и сердечно-сосудистых заболеваний. Ожирение как первопричина дисбаланса адипокинов является важнейшим фактором риска возникновения гипертензии, атеросклероза и инфаркта миокарда. Это обусловливает важность экспериментальных и клинических исследований биологии адипокинов для определения перспективных направлений в терапии сердечно-сосудистых заболеваний. Настоящий обзор сфокусирован на рассмотрении роли адипонектина, лептина, хемерина, оментина и висфатина в физиологических и патофизиологических процессах в сердечно-сосудистой системе.
1. Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr. 1987;45(1Suppl):277-282. doi:10.1093/ajcn/45.1.277
2. Flier JS, Cook KS, UsherP, SpiegelmanBM. Severely impaired adipsin expression in genetic and acquired obesity. Science. 1987;237(4813):405-408. doi:10.1126/science.3299706
3. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425-432. doi:10.1038/372425a0
4. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271 (18):10697-10703. doi:10.1074/jbc.271.18.10697
5. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221(2):286-289. doi:10.1006/bbrc.1996.0587
6. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem. 1996;120(4):803-812. doi:10.1093/oxfordjournals.jbchem.a021483
7. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270(45):26746-26749. doi:10.1074/jbc.270.45.26746. PMID:7592907
8. Katira A, Tan PH. Evolving role of adiponectin in cancer-controversies and update. Cancer Biol Med. 2016;13(1):101—119. doi:10.20892/j.issn.2095-3941.2015.0092. PMID:27144066
9. Fields DA, Schneider CR, Pavela G. A narrative review of the associations between six bioactive components in breastmilk and infant adiposity. Obesity. 2016;24:1213-1221. doi:10.1002/oby.21519. PMID: 27151491
10. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem. 2003;278(41 ):40352-40363. doi:10.1074/jbc.M300365200
11. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA. 2001;98(4):2005-2010. doi:10.1073/pnas.041591798
12. Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci. 2017;18(6):1321. doi:10.3390/ijms18061321. PMID: 28635626
13. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes. 2003;52(2):268-276. doi:10.2337/diabetes.52.2.268
14. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79-83. doi:10.1006/bbrc.1999.0255
15. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7(8):941-946. doi:10.1038/90984
16. Medina-Bravo P, Meza-Santibanez R, Rosas-Fernandez P, Galvan-Duarte R, Saucedo-Garcia R, Velazquez-Lopez L et al. Decrease in serum adiponectin levels associated with visceral fat accumulation independent of pubertal stage in children and adolescents. Arch Med Res. 2011 ;42(2): 115—121. doi: 10.1016/j.arcmed.2011.03.002
17. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation. 2006;114 (7):623-629. doi:10.1161/CIRCULATIONAHA.106.618918
18. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43(6):1318-1323. doi: 10.1161/01.HYP.0000129281.03801.4b
19. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press. 2004;13 (4):236-242.
20. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAm MedAssoc. 2004;291(4):1730-1737. doi: 10.1001/jama.291.14.1730
21. Andreas NJ, Hyde MJ, Gale C, Parkinson JR, Jeffries S, Holmes E. Effect of maternal body mass index on hormones in breast milk: A systematic review. PLoS ONE. 2014;9:e115043. doi:10.1371/journal.pone.0115043
22. Chan D, Goruk S, Becker AB, Subbarao P, Mandhane PJ, Turvey SE. Adiponectin; leptin and insulin in breast milk: Associations with maternal characteristics and infant body composition in the first year of life. Int J Obes. 2018;42:36-43. doi:10.1038/ijo.2017.189
23. Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T, Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem. 2004;279(27):28670-28674. doi: 10.1074/jbc.M402558200
24. Kondo M, Shibata R, Miura R, Shimano M, Kondo K, Li P et al. Caloric restriction stimulates revascularization in response to ischemia via adiponectin-mediated activation of endothelial nitric-oxide synthase. J Biol Chem. 2009;284(3):1718-1724. doi: 10.1074/jbc.M805301200
25. Nishimura M, Izumiya Y, Higuchi A, Shibata R, Qiu J, Kudo C et al. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation. 2008;117 (2):216-223. doi:10.1161/CIRCULA-TIONAHA.107.725044
26. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension. 2006;47(6):1108-1116. doi: 10.1161/01.HYP.0000222368.43759.a1
27. Li R, Wang WQ, Zhang H, Yang X, Fan Q, Christopher TA et al. Adiponectin improves endothelial function in hyperlipi-demic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. Am J Physiol Endocrinol Metab. 2007;293(6):1703-1708. doi:10.1152/ajpendo.00462.2007
28. SerafiAS. Adipocytokines in blood pressure variations and hypertension: An overview. Int J Biol Biotech. 2018;15:1-12.
29. DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol. 2014;10(6):364-376. doi:10.1038/nrendo.2014.44
30. Rojas E, Rodriguez-Molina D, Bolli P, Israili ZH, Faria J, Fidilio E et al. The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep. 2014;16(8):463. doi:10.1007/s11906-014-0463-7
31. Okamoto Y, Folco EJ, Minami M, Wara AK, Feinberg MW, Sukhova GK et al. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res. 2008;102 (2):218-225. doi:10.1161/CIRCRESAHA.107.164988
32. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106(22):2767-2770. doi: 10.1161/01.cir.0000042707.50032.19
33. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem. 2003;278(4):2461-2468. doi:10.1074/jbc.M2090 33200
34. Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem. 2004;279(2): 1304-1309. doi: 10.1074/jbc.M310389200
35. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003;278(45):45021-45026. doi:10.1074/jbc.M307878200
36. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res. 2004;94 (4):e27-e31. doi:10.1161/01.RES.0000119921.86460.37
37. Ohashi K, Ouchi N, Sato K, Higuchi A, Ishikawa TO, Herschman HR et al. Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism. Mol Cell Biol. 2009;29(13):3487-3499. doi:10.1128/MCB.00126-09
38. Ouchi N, Kihara S,Arita Y, Maeda K, Kuriyama H, Okamoto Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100(25):2473-2476. doi:10.1161/01.cir.100.25.2473
39. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000;102(11): 1296-1301. doi: 10.1161/01.cir.102.11.1296
40. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002;105(24):2893-2898. doi: 10.1161/01.cir.0000018622.84402.ff
41. Ding M, Xie Y, Wagner RJ, Jin Y, Carrao AC, Liu LS et al. Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of rapamycin complex 1 and FoxO4. Arterioscler Thromb Vasc Biol. 2011;31(6): 1403-1410. doi:10.1161/ATVBAHA.110.216804
42. Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res. 2005;67(4):705-713. doi: 10.1016/j.cardiores.2005.04.018
43. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA et al. Adiponectin cardioprotection after myocardial ischemia/ reperfusion involves the reduction of oxidative/nitrative stress. Circulation. 2007;115 (11):1408-1416. doi:10.1161/CIRCULA-TTONAHA.106.666941
44. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 2005;11(10): 109 6—1103. doi:10.1038/nm1295
45. Sam F, Duhaney TA, Sato K, Wilson RM, Ohashi K, Sono-Romanelli S et al. Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. Endocrinology. 2010;151(1):322—331. doi:10.1210/en.2009-0806
46. Shibata R, Izumiya Y, Sato K, Papanicolaou K, Kihara S, Colucci WS et al. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol. 2007;42(6):1065-1074. doi:10.1016/j.yjmcc.2007. 03.808
47. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423(6941):762-769. doi:10.1038/nature01705
48. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M et al. Targeted disruption ofAdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13(3):332-339. doi:10.1038/nm1557
49. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA. 2004;101 (28):10308-10313. doi:10.1073/pnas.0403382101
50. Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest. 2010;120(12):4342-4352. doi: 10.1172/JCI43464
51. Parker-Duffen JL, Nakamura K, Silver M, Kikuchi R, Tigges U, Yoshida S et al. T-cadherin is essential for adiponectin-mediated revascularization. J Biol Chem. 2013;288(34):24886-24897. doi: 10.1074/jbc.M113.454835
52. Ivanov D, Philippova M, Antropova J, Gubaeva F, Iljinskaya O, Tararak E et al. Expression of cell adhesion molecule T-cadherin in the human vasculature. Histochem Cell Biol. 2001;115 (3):231-242.
53. Hebbard LW, Garlatti M, Young LJ, Cardiff RD, Oshi-ma RG, Ranscht B. T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res. 2008;68(5):1407-1416. doi:10.1158/0008-5472.CAN-07-2953
54. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145(5):2273-2282. doi:10.1210/en.2003-1336
55. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21 (6):697-738. doi:10.1210/edrv.21.6.0415
56. Friedman JM. Leptin, leptin receptors, and the control of body weight. Nutr Rev. 1998;56(2Pt2): s38-s46. Discussion s54-75. doi: 10.1111 /j.1753 -4887.1998.tb01685.x
57. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995;1(11):1155-1161. doi:10.1038/nm1195-1155
58. Friedman JM, Halaas JL. Leptin and the regulation ofbody weight in mammals. Nature. 1998;395(6704):763-770. doi:10. 1038/27376
59. Howard JK, Flier JS. Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab. 2006;17 (9):365-371. doi:10.1016/j.tem.2006.09.007
60. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341(12):879-884. doi:10.1056/NEJM199909163411204
61. Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart. Cardiov Res. 2008;79 (2):279-286. doi:10.1093/cvr/cvn115
62. Mattu HS, Randeva HS. Role ofadipokines in cardiovascular disease. J Endocrinol. 2013;216(1); T17-36. doi:10.1530/JOE-12-0232
63. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension. 1998;31 (1Pt2): 409-414. doi: 10.1161/01.hyp.31.1.409
64. Satoh N, Ogawa Y, Katsuura G, Numata Y, Tsuji T, Hayase M et al. Sympathetic activation of leptin via the ventromedial hypothalamus: leptin-induced increase in catecholamine secretion. Diabetes. 1999;48(9):1787-1793. doi:10.2337/diabetes.48.9.1787
65. Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F, Gami AS, Sert Kuniyoshi FH, Wolk R et al. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population. Am J Cardiol. 2007;100 (2):234-239. doi:10.1016/j.amjcard.2007.02.088
66. Gruen ML, Hao M, Piston DW, Hasty AH. Leptin requires canonical migratory signaling pathways for induction of monocyte and macrophage chemotaxis. Am J Physiol Cell Physiol. 2007;293 (5):C1481-C1488. doi:10.1152/ajpcell.00062.2007
67. Porreca E, Di Febbo C, Moretta V, AngeliniA, Guglielmi MD, Di Nisio M et al. Circulating leptin is associated with oxidized LDL in postmenopausal women. Atherosclerosis. 2004;175(1):139-143. doi:10.1016/j.atherosclerosis. 2004.03.010
68. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol. 2003;54(4):469-487.
69. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006;189(1):47-60. doi:10.1016/j.atherosclerosis.2006.03.003
70. Fujimaki S, Kanda T, Fujita K, Tamura J, Kobayashi I. The significance of measuring plasma leptin in acute myocardial infarction. J Int Med Res. 2001;29(2):108-113. doi:10.1177/147323000102900207
71. Schulze PC, Biolo A, Gopal D, Shahzad K, Balog J, Fish M et al. Dynamics in insulin resistance and plasma levels of adipokines in patients with acute decompensated and chronic stable heart failure. J Card Fail. 2011;17(12):1004-1011. doi: 10.1016/j.cardfail.2011.08.010
72. Barouch LA, Berkowitz DE, Harrison RW, O’Donnell CP, Hare JM. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation. 2003;108(6):754-759. doi: 10.1161/01.CIR.0000083716.82622.FD
73. Kanda T, Takahashi T, Kudo S, Takeda T, Tsugawa H, Takekoshi N. Leptin deficiency enhances myocardial necrosis and lethality in a murine model of viral myocarditis. Life Sci. 2004;75 (12):1435-1447. doi:10.1016/j.lfs.2004.03.012
74. McGaffin KR, Zou B, McTiernan CF, O'Donnell CP. Leptin attenuates cardiac apoptosis after chronic ischaemic injury. Cardiovasc Res. 2009;83 (2):313-324. doi:10.1093/cvr/cvp071
75. Schiekofer S, Galasso G, Sato K, Kraus BJ, Walsh K. Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network. Arterioscler Thromb Vasc Biol. 2005;25(8):1603-1609. doi:10.1161/01.ATV.0000171994.89106.ca
76. Duvic M, Nagpal S,Asano AT, Chandraratna RA. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol. 1997;37(2Pt3): S18-24.
77. Wittamer V, Franssen JD, Vulcano M, Mrjolet JF, Le Poul E, Migeotte I et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003;198(7):977-985. doi:10.1084/jem.20030382
78. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148 (10):4687-4694. doi:10.1210/en.2007-0175
79. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007;282(38):28175-28188. doi:10.1074/jbc.M700793200
80. Roh SG, Song SH, Choi K, Katoh K, Wittamer V, Parmentier M et al. Chemerin — a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun. 2007;362(4):1013-1018. doi:10.1016/j.bbrc.2007.08.104
81. Takahashi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS, Kitazawa R et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett. 2008;582(5):573-578. doi: 10.1016/j.febslet.2008.01.023
82. Sell H, Divoux A, Poitou C, Basdevant A, Bouillot JL, Bedossa P et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2010;95 (6):2892-2896. doi:10.1210/jc.2009-2374
83. Zabel BA, Ohyama T, Zuniga L, Kim JY, Johnston B, Allen SJ et al. Chemokine-like receptor 1 expression by macrophages in vivo: regulation by TGF-beta and TLR ligands. Exp Hematol. 2006;34 (8):1106—1114. doi:10.1016/j.exphem.2006.03.011
84. Wittamer V, Bondue B, GuillabertA, Vassart G, Parmentier M, Communi D. Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol. 2005;175 (5):487-493. doi:10.4049/jimmunol.175.1.487
85. Weigert J, Obermeier F, Neumeier M, Wanninger J, Filarsky M, Bauer S et al. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn’s disease. Inflamm Bowel Dis. 2010;16(4):630-637. doi: 10.1002/ibd.21091
86. Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population — a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152(2):217-221.
87. Bozaoglu K, Curran JE, Stocker CJ, Zaibi MS, Segal D, Konstantopoulos N et al. Chemerin, a novel adipokine in the regulation of angiogenesis. J Clin Endocrinol Metab. 2010;95 (5) :2476-2485. doi:10.1210/jc.2010-0042
88. Hart R, Greaves DR. Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. J Immunol. 2010;185 (6) :3728-3739. doi:10.4049/jimmunol.0902154
89. Spiroglou SG, Kostopoulos CG, Varakis JN, Papadaki HH. Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J Atheroscler Thromb. 2010;17(2):115—130. doi: 10.5551/jat.1735
90. Gao X, Mi S, Zhang F, Gong F, Lai Y, Gao F et al. Association of chemerin mRNA expression in human epicardial adipose tissue with coronary atherosclerosis. Cardiovasc Diabetol. 2011;10:87. doi:10.1186/1475-2840-10-87
91. Becker M, Rabe K, Lebherz C, Zugwurst J, Goke B, Parhofer KG et al. Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes. 2010;59(11):2898-2903. doi:10.2337/db10-0362
92. Hah YJ, Kim NK, Kim MK, Kim HS, Hur SH, Yoon HJ et al. Relationship between chemerin levels and cardiometabolic parameters and degree of coronary stenosis in Korean patients with coronary artery disease. Diabetes Metab J. 2011;35(3):248-254. doi:10.4093/dmj.2011.35.3.248
93. Lu B, Zhao M, Jiang W, Ma J, Yang C, Shao J et al. Independent association of circulating level of chemerin with functional and early morphological vascular changes in newly diagnosed type 2 diabetic patients. Medicine (Baltimore). 2015;94 (47):e1990. doi:10.1097/MD.0000000000001990
94. Yoo HJ, Choi HY, Yang SJ, Kim HY, Seo JA, Kim SG et al. Circulating chemerin level is independently correlated with arterial stiffness. J Atheroscler Thromb. 2011;19(1):59—66. doi:10.5551/jat.9647
95. Tsuji S, Uehori J, Matsumoto M, Suzuki Y, Matsuhisa A, Toyoshima K et al. Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem. 2001;276(26):23456-23463. doi:10.1074/jbc.M103162200
96. Suzuki YA, Shin K, Lonnerdal B. Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry. 2001;40(51):15771-15779. doi:10.1021/bi0155899
97. Lee JK, Schnee J, Pang M, Wolfert M, Baum LG, Moremen KW et al. Human homologs of the Xenopus oocyte cortical granule lectin XL35. Glycobiology. 2001;11(1):65—73. doi: 10.1093/glycob/11.1.65
98. SchafflerA, Neumeier M, Herfarth H, FurstA, Scholmerich J, Buchler C. Genomic structure of human omentin, a new adipo-cytokine expressed in omental adipose tissue. Biochim Biophys Acta. 2005;1732(1-3):96-102. doi:10.1016/j.bbaexp.2005.11.005
99. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 2006;290(6): E1253-1261. doi:10.1152/ajpendo.00572.2004
100. Liang W, Ye DD. The potential ofadipokines as biomarkers and therapeutic agents for vascular complications in type 2 diabetes mellitus. Cytokine Growth Factor Rev. 2019;48:32-39.
101. Fain JN, Sacks HS, Buehrer B, Bahouth SW, Garrett E, Wolf RY et al. Identification of omentin mRNA in human epicardial adipose tissue: comparison to omentin in subcutaneous, internal mammary artery periadventitial and visceral abdominal depots. Int J Obes (Lond). 2008;32(5):810-815. doi: 10.1038/sj.ijo.0803790
102. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernandez-Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring). 2011;19(8):1552-1559. doi:10.1038/oby.2010.351
103. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007;56(6)1655-1661. doi: 10.2337/db06-1506
104. Tan BK,Adya R, Farhatullah S, Lewandowski KC, O’Hare P, Lehnert H et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes. 2008;57(4):801-808. doi:10.2337/db07-0990
105. Zhong X, Zhang HY, Tan H, Zhou Y, Liu FL, Chen FQ et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin. 2011;32(7):873-878. doi:10.1038/aps.2011.26
106. Moreno-Navarrete JM, Catalan V, Ortega F, Gomez-Ambrosi J, Ricart W, Fruhbeck G et al. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond). 2010;7:27. doi: 10.1186/1743-7075-7-27
107. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun. 2010;393(4):668-672. doi:10.1016/j.bbrc.2010.02.053
108. Prats-PuigA, Bassols J, Bargallo E, Mas-Parareda M, Ribot R, Soriano-Rodriguez P et al. Toward an early marker of metabolic dysfunction: omentin-1 in prepubertal children. Obesity (Silver Spring). 2011;19(9):1905-1907. doi:10.1038/oby.2011.198
109. Maruyama S, Shibata R, Kikuchi R, Izumiya Y, Rokutanda T, Araki S et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J Biol Chem. 2012;287 (1):408-417. doi:10.1074/jbc.M111.261818
110. Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med. 2010;20(5):143-148. doi: 10.1016/j.tcm.2010.12.002
111. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Re Commun. 2011;408(2):339-343. doi:10.1016/j.bbrc. 2011.04.039
112. Liu R, Wang X, Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract. 2011;93(1):21-25. doi:10.1016/j.diabres.2011.03.001
113. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest. 2004;113(9):1318-1327. doi:10.1172/JCI19930
114. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178(3):1748-1758. doi:10.4049/jimmunol.178.3.1748
115. Ye SQ, Simon BA, Maloney JP, Zambelli-Weiner A, Gao L, Grant A et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med. 2005;171(4):361-370. doi:10.1164/rccm.200404-563OC
116. Nowell MA, Richards PJ, Fielding CA, Ognjanovic S, Topley N, Williams AS et al. Regulation of pre-B cell colonyenhancing factor by STAT-3-dependent interleukin-6 transsignaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2006;54(7):2084-2095. doi:10.1002/art.21942
117. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994;14(2):1431-1437. doi:10.1128/mcb.14.2.1431
118. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 2002;32(11):3225-3234. doi:10.1002/1521—4141(200211)32:113.0.CO;2-L
119. Ziegler M. New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. Eur J Biochem. 2000;267(6):1550-1564. doi:10.1046/j.1432-1327.2000.01187.x
120. FukuharaA, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426-430. doi:10.1126/science.1097243
121. Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colonyenhancing factor. FEBS Lett. 2003;544(1-3):74-78. doi:10.1016/s0014-5793(03)00476-9
122. Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee MJ et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab. 2007;92(2):666-672. doi: 10.1210/jc.2006-1303
123. Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O et al. The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr. 2006;43(4):548-549. doi:10.1097/01.mpg.0000235749.50820.b3
124. Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab. 2006;91(12):5022-5028. doi:10.1210/jc.2006-0936
125. Krzyzanowska K, Krugluger W, Mittermayer F, Rahman R, Haider D, Shnawa N et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond). 2006;110 (5):605-609. doi:10.1042/CS20050363
126. Haider DG, Pleiner J, Francesconi M, Wiesinger GF, Muller M, Wolzt M. Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes. J Clin Endocrinol Metab. 2006;91(11):4702-4704. doi:10.1210/jc.2006-1013
127. Retnakaran R, Youn BS, Liu Y, Hanley AJ, Lee NS, Park JW et al. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol (Oxf). 2008;69(6):885-893. doi: 10.1111/j.1365-2265.2008.03264.x
128. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab. 2006;91(4):1578-1581. doi:10.1210/jc.2005-2248
129. Chan TF, Chen YL, Lee CH, Chou FH, Wu LC, Jong SB et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig. 2006;13 (5):364-367. doi:10.1016/j.jsgi.2006.04.007
130. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006;91(8)3165-3170. doi:10.1210/jc.2006-0361
131. Krzyzanowska K, Mittermayer F, Krugluger W, Kopp HP, Schernthaner G. Increase in visfatin after weight loss induced by gastroplastic surgery. Obesity (Silver Spring). 2006;14(11):1886-1889. doi:10.1038/oby.2006.219
132. Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem. 2008;15 (18):1851-1862. doi:10.2174/092986708785133004
133. Bae SK, Kim SR, Kim JG, Kim JY, Koo TH, Jang HO et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett. 2006;580(17):4105-4113. doi:10.1016/j.febslet.2006.06.052
134. Segawa K, Fukuhara A, Hosogai N, Morita K, Okuno Y, Tanaka M et al. Visfatin in adipocytes is upregulated by hypoxia through HIF1alpha-dependent mechanism. Biochem Biophys Res Commun. 2006;349(3):875-882. doi:10.1016/j.bbrc.2006.07.083
135. van der Veer E, Nong Z, O’Neil C, Urquhart B, Freeman D, Pickering JG. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res. 2005;97(5):25-34. doi: 10.1161/01.RES.0000173298.38808.27
136. RongvauxA, Galli M, Denanglaire S, Van Gool F, Dreze PL, Szpirer C et al. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol. 2008;181(7):4685-4695. doi:10.4049/jimmunol.181.7.4685
137. Lim SY, Davidson SM, Paramanathan AJ, Smith CC, Yellon DM, Hausenloy DJ. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med. 2008;12(4):1395-1403. doi:10.1111/j.1582-4934.2008.00332.x
138. Kim SR, Bae SK, Choi KS, Park SY, Jun HO, Lee JY et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun. 2007;357 (1):150-156. doi:10.1016/j.bbrc.2007.03.105
139. Dahl TB, Yndestad A, Skjelland M, Oie E, Dahl A, Michelsen A et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007; 115(8):972-980. doi:10.1161/CIRCULATIONAHA.106.665893
140. Dahl T, Ranheim T, Holm S, Berge R, Aukrust P, Halvorsen B. Nicotinamide phosphoribosyltransferase and lipid accumulation in macrophages. Eur J Clin Invest. 2011 ;41 (10):1098—104. doi: 10.1111/j.1365-2362.2011.02515.x